Europe Molecular Biosensors Market at a CAGR of 6% BY 2023; Dominated by Top Competitors (Siemens Healthcare, LifeSensors, Nova Biomedical Corporation, Abbott Laboratories, Johnson and Johnson, Medtronic, F. Hoffmann La Roche, and Bayer AG)

Europe Molecular Biosensors Market Highlights
The European molecular biosensors market is expected to register a CAGR of 6% during the forecast period, 2018 to 2023. Germany dominates the market due to the increasing demand for point of care testing in the region.

Get your sample report now @ https://marketprognosis.com/sample-request/17096
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Increasing Prevalence of Chronic and Lifestyle-induced Diseases
The incidence of chronic diseases is relatively high in Europe. According to WHO, cerebrovascular disease or stroke accounted for approximately 20% of all deaths and 9% of total disease burden in 2015 in Europe. Mortality and disease burden from diabetes mellitus is also increasing in this region. Chronic obstructive pulmonary disease (COPD) is also one of the leading causes of premature death in Europe. Biosensors are used in the detection of disease progression. The increasing prevalence of chronic and lifestyle-induced diseases is driving the growth of the European molecular biosensor market.
Additionally, increasing demand for point of care testing and increasing application of biosensors in various industries are also fueling the growth of the European molecular biosensor market.

Key Developments in the Market
January 2018 - Scientists developed an ultra-thin, flexible biosensor for real-time glucose tracking, which can be incorporated into watches or contact lenses.

The major players include –
Siemens Healthcare, LifeSensors, Inc., Nova Biomedical Corporation, Abbott Laboratories, Inc., Johnson and Johnson, Medtronic, Inc., F. Hoffmann La Roche, and Bayer AG, among others.

Get Discount on this report @ https://marketprognosis.com/discount-request/17096
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Reimbursement Policies Issues in Healthcare Systems
In European countries, there are various issues in reimbursement policies in the healthcare system. Healthcare in EU is either financed through general taxation or by contributions to health insurance funds. These health insurance funds are highly expensive. Doctors in Germany are blaming the government-set prices for not letting them regain their investment. Many Italian regions are going bankrupt due to the funding of medicine.

Germany to Dominate the Market
Germany dominates the molecular biosensor market due to the increasing demand for point of care tests, increase in chronic disease, and R&D investment, which is increasing the scope of the European molecular biosensor market.

For More Information, Please Visit @ https://marketprognosis.com/enquiry/17096
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.